Cedars-Sinai investigators have identified a genetic variant that increases people's risk of developing perianal Crohn's disease, the most debilitating manifestation of Crohn's disease. Science X ...

SAN FRANCISCO -- The investigational complement-targeting agent claseprubart was safe and led to significant improvements in generalized myasthenia gravis (MG), the phase II MaGic trial showed. The ...

Meeting the needs of the community is one of North Idaho College President Nick Swayne’s main goals. So when he saw a growing trend toward classical education in the Inland Northwest with charter, ...

Click here to view the Virtual Industry Forum presentation live on October 29, 2025 or watch the archived event upon completion. About Claseprubart (DNTH103) Claseprubart is an investigational, ...

The objective of this study was to evaluate the methodology to establish the hemolytic activity of alternative complement pathway as an indicator of the innate immunity in Brazilian fish pacu ...

ARCHER II trial evaluates vonaprument's efficacy in preventing vision loss in advanced AMD/GA, with over 630 patients enrolled globally. Vonaprument selectively inhibits C1q, addressing ...

Please provide your email address to receive an email when new articles are posted on . SAR446597 is designed to inhibit C1s and factor Bb in the complement pathway. Fast track designation expedites ...

Purpose: To evaluate whether low CH50 (a comprehensive measure of hemolytic activity of the classical complement pathway) is associated with infection-related coagulopathy, organ dysfunction, and poor ...

SEOUL, South Korea--(BUSINESS WIRE)--ImmunAbs Inc., a clinical-stage biotech specializing in developing antibody therapeutics, today announced that the U.S. Food and Drug Administration has cleared ...